Back to Search
Start Over
Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
- Source :
-
European Journal of Nuclear Medicine & Molecular Imaging . Mar2018, Vol. 45 Issue 3, p513-514. 2p. 1 Black and White Photograph. - Publication Year :
- 2018
-
Abstract
- The article focuses on the treatment of patients with metastasized castration resistant prostate cancer. Topics discussed include use of 177 lutetium prostate-specific membrane antigen inhibitor 617 radioligand therapy for the treatment of the same; European Society of Oncology annual meeting in Madrid on the same; and providing supportive care for the same.
Details
- Language :
- English
- ISSN :
- 16197070
- Volume :
- 45
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- European Journal of Nuclear Medicine & Molecular Imaging
- Publication Type :
- Academic Journal
- Accession number :
- 127610057
- Full Text :
- https://doi.org/10.1007/s00259-017-3892-0